Welcome
Support Centre
18 March 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
The Efficacy of Self-MONitoring of blood glucose in patients with type two diabetes mellitus
ISRCTN ISRCTN49814766
ClinicalTrials.gov identifier
Public title The Efficacy of Self-MONitoring of blood glucose in patients with type two diabetes mellitus
Scientific title
Acronym ESMON
Serial number at source RRG5.7
Study hypothesis Self blood glucose monitoring is not associated with benefit in terms of improved glycaemic control or psychological indices.
Ethics approval Ethics approval received from:
1. University of Ulster Ethics Committee on the 17th August 2001 (ref: 01/29)
2. Altnagelvin Hospitals Health and Social Services Trust on the 14th June 2000
Study design Prospective randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Type two diabetes mellitus
Participants - inclusion criteria 1. Patients with newly diagnosed type two diabetes
2. Aged less than 70 years old
Participants - exclusion criteria 1. Secondary diabetes
2. Insulin use
3. Previous monitoring
4. Pregnancy
5. Previous malignancy
6. Major illness within 6 months (including major surgery, myocardial infarction (MI), acute coronary syndrome, stroke, acute limb ischaemia)
7. Liver disease
8. Creatinine > 150 µmol/L
9. Proteinuria > 0.5 g/ 24 h
10. Chronic use of oral steroids
11. Alcohol abuse
Anticipated start date 01/12/2000
Anticipated end date 01/01/2006
Status of trial Completed
Patient information material
Target number of participants 200
Interventions Self monitoring of blood glucose versus non-monitoring.
Primary outcome measure(s) 1. Between-group differences in glycaemic control (HbA1c)
2. Between-group differences in psychological indices
3. Between-group differences in reported hypoglycaemia
Secondary outcome measure(s) 1. Between-group differences in body mass index (BMI)
2. Between-group differences in oral hypoglycaemic drug usage
3. Longitudinal within-group changes in HbA1c, BMI and psychological indices
Sources of funding Northern Ireland Department of Health, Research and Development Office (UK)
Trial website
Publications Results in http://www.ncbi.nlm.nih.gov/pubmed/18420662
Contact name Prof  Vivien  Coates
  Address School of Nursing
University of Ulster
Coleraine campus
  City/town Coleraine
  Zip/Postcode BT52 1SA
  Country United Kingdom
  Email ve.coates@ulster.ac.uk
Sponsor University of Ulster (UK)
  Address c/o Prof Vivien Coates
School of Nursing
Coleraine campus
  City/town Coleraine
  Zip/Postcode BT52 1SA
  Country United Kingdom
  Email ve.coates@ulster.ac.uk
  Sponsor website: http://www.ulster.ac.uk
Date applied 08/01/2007
Last edited 21/04/2008
Date ISRCTN assigned 26/02/2007
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© ISRCTN


BioMed Central